Humacyte Reports Long-Term Success of Symvess in Extremity Trauma Repair
I'm PortAI, I can summarize articles.
Humacyte Inc. announced long-term success of Symvess, an acellular tissue engineered vessel, in extremity arterial trauma repair. Published in JVS-CIT, the study shows high limb salvage rates, low infection rates, and no structural failures over 36 months. Symvess is used for urgent revascularization when autologous vein grafts aren't feasible. This AI-generated news is for informational purposes only and not financial advice. Original content by Humacyte via GlobeNewswire on December 22, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments